GlycoMimetics Receives $15 Million Payment from Pfizer in Connection with Planned Initiation of Phase 3 Trial
"Moving into Phase 3 will be a significant step forward in our effort to
potentially address the unmet needs of individuals with sickle cell
disease. With the commitment of our collaborator, Pfizer, we hope this
will enable us to bring to patients, caregivers and physicians an
important new medication for treatment of vaso-occlusive crisis or VOC
of sickle cell disease," said
About VOC
Vaso-occlusive crisis of sickle cell (VOC) is a condition that
represents a significant unmet medical need. Sickle cell disease is one
of the most prevalent genetic disorders in the U.S., affecting over
90,000 people. It is a chronic condition causing substantial illness and
death. For example, VOC is responsible for more than 73,000
hospitalizations per year in the U.S. with an average stay of
approximately six days. Rivipansel has received both Orphan Drug and
Fast Track status for VOC from the
The main clinical feature of sickle cell disease is periodic painful VOC episodes, known as VOC or pain crises, which result in significant clinical complications. Treatment for VOC today consists primarily of supportive therapy, in the form of hydration and pain control, typically requiring extended hospitalization. No other therapies have been effective in aborting a VOC once it has begun. Rivipansel is intended to treat VOC by inhibiting the cell activation and enhanced cell adhesion, which causes the ischemia and pain.
About
This press release contains forward-looking statements regarding
GlycoMimetics' planned activities with respect to the clinical
development of rivipansel (GMI-1070) and other matters. Actual results
may differ materially from those in these forward-looking statements.
For a further description of the risks associated with these statements,
as well as other risks facing
bhahn@glycomimetics.com
Source:
News Provided by Acquire Media